鲁抗医药发预减，预计2025年度归母净利润1.1亿元-1.45亿元，同比减少63.26%-72.13%

Core Viewpoint - LuKang Pharmaceutical (600789.SH) expects a significant decline in net profit for the fiscal year 2025, projecting a net profit attributable to shareholders of the parent company between 110 million to 145 million yuan, representing a decrease of approximately 249.62 million to 284.62 million yuan compared to the previous year, which translates to a year-on-year decline of 63.26% to 72.13% [1] Financial Summary - The projected net profit for 2025 is estimated to be between 110 million to 145 million yuan [1] - The expected decrease in net profit compared to the previous year is between 249.62 million to 284.62 million yuan [1] - The year-on-year percentage decline in net profit is forecasted to be between 63.26% and 72.13% [1]